Wanbang Biotech Faces Dual Accountability, Anticipates Net Loss of 4.7-5.7 Billion Yuan in 2025
In just three years, Hebang Bio (603077.SH) has experienced a sharp reversal from peak performance to heavy losses. Recently, the company received dual...